Mechanisms of liver fibrosis: New insights into an old problem

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 4, 2006, Pages 489-495

  Wells, Rebecca G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CASPASE INHIBITOR; COLCHICINE; COLLAGEN; CYTOKINE; HERBACEOUS AGENT; OSTEOGENIC PROTEIN 1; PROTECTIVE AGENT; S ADENOSYLMETHIONINE; SCATTER FACTOR; STEROID; TOCOPHEROL; TRANSFORMING GROWTH FACTOR BETA;

CELL ACTIVATION; CELL POPULATION; CLINICAL PROTOCOL; DISEASE MODEL; EXTRACELLULAR MATRIX; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REVIEW; STELLATE CELL;

EID: 33847044032     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.10.003     Document Type: Review

References (45)

1. Schuppan D., et al. Matrix as a modulator of hepatic fibrogenesis. Semin. Liver Dis. 21 (2001) 351-372
2. Desmouliere A., et al. Extracellular matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic fibrosis in the rat. Lab. Invest. 76 (1997) 765-778
3. Issa R., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 126 (2004) 1795-1808
4. Languino L.R., and Wells R.G. Integrins. In: Arias I.M. (Ed). The Liver: Biology and Pathobiology (2001), Lippincott Williams & Wilkins 475-482
5. Zhou X., et al. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem. 279 (2004) 23996-24006
6. Takahara T., et al. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 26 (1997) 1521-1529
7. Benyon R.C., and Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 21 (2001) 373-384
8. Herbst H., et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am. J. Pathol. 150 (1997) 1647-1659
9. Tomasek J.J., et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3 (2002) 349-363
10. Friedman S.L. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nat. Clin. Pract. Gastroenterol. Hepatol. 1 (2004) 98-105
11. Knittel T., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117 (1999) 1205-1221
12. Magness S.T., et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 40 (2004) 1151-1159
13. Guyot C., et al. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int. J. Biochem. Cell Biol. 38 (2006) 135-151
14. Kinnman N., and Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci. 7 (2002) d496-d503
15. Wells R.G., et al. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett. 559 (2004) 107-110
16. Russo F.P., et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130 (2006) 1807-1821
17. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112 (2003) 1776-1784
18. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15 (2004) 1-12
19. Xia J.L., et al. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am. J. Pathol. 168 (2006) 1500-1512
20. Herbst H., et al. Heterogeneity of liver cells expressing procollagen types I and IV in vivo. Histochem. Cell Biol. 107 (1997) 399-409
21. Gressner A.M., et al. Roles of TGF-beta in hepatic fibrosis. Front Biosci. 7 (2002) d793-d807
22. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 85 (2004) 47-64
23. Bataller R., and Brenner D.A. Liver fibrosis. J. Clin. Invest. 115 (2005) 209-218
24. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci. 7 (2002) d1899-d1914
25. Bataller R., et al. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid. Redox. Signal 7 (2005) 1346-1355
26. Rockey D.C. Vascular mediators in the injured liver. Hepatology 37 (2003) 4-12
27. Ding X., et al. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 166 (2005) 1655-1669
28. She H., et al. Adipogenic transcriptional regulation of hepatic stellate cells. J. Biol. Chem. 280 (2005) 4959-4967
29. Yang L., et al. Regulation of peroxisome proliferator-activated receptor {gamma} in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G902-G911
30. Lorena D., et al. Fibrillin-1 expression in normal and fibrotic rat liver and in cultured hepatic fibroblastic cells: modulation by mechanical stress and role in cell adhesion. Lab. Invest. 84 (2004) 203-212
31. Maher J.J. Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21 (2001) 417-426
32. Vinas O., et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 38 (2003) 919-929
33. Jarnagin W.R., et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J. Cell Biol. 127 6 Pt 2 (1994) 2037-2048
34. Muro A.F., et al. Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. J. Cell Biol. 162 (2003) 149-160
35. Tan M.H., et al. Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104 (2004) 11-18
36. Bataller R., et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest. 112 (2003) 1383-1394
37. Canbay A., et al. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 (2004) 273-278
38. Mann D.A., and Smart D.E. Transcriptional regulation of hepatic stellate cell activation. Gut 50 (2002) 891-896
39. Bataller R., et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 126 (2004) 529-540
40. Purohit V., and Brenner D.A. Mechanisms of alcohol-induced hepatic fibrosis: a summary of the Ron Thurman Symposium. Hepatology 43 (2006) 872-878
41. Marra F., et al. Review article: the pathogenesis of fibrosis in non-alcoholic steatohepatitis. Aliment Pharmacol. Ther. 22 Suppl 2 (2005) 44-47
42. Schaffler A., et al. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 273-280
43. Iredale J.P., et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J. Clin. Invest. 102 (1998) 538-549
44. Poynard T., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
45. Wanless I.R., et al. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch. Pathol. Lab. Med. 124 (2000) 1599-1607